Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Aldeyra Therapeutics, Inc.

ALDX

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Last trade $0.6963
Day change +$0.0267 (+3.99%)
Day range $0.655 – $0.702
Volume 633,011
Market cap $40M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$40.44M
Price / earnings
—
Price / book
1.15×
Price / sales
—
EV / sales
—
EV / EBITDA
0.03×

Profitability

Earnings per share
-$0.32
Return on assets
-44.09%
Return on equity
-54.3%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.45×
Quick ratio
5.45×
Cash ratio
5.2×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALDX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.3M$2.37M$1.14M$2.36M$2.57M$1.66M$3M$1.95M
Research and development$1.84M$3.48M$2.41M$4.3M$5.43M$8.51M$7.42M$14.63M
Total operating expenses$4.14M$5.85M$3.55M$6.67M$8M$10.17M$10.43M$16.58M
Operating income-$4.14M-$5.85M-$3.55M-$6.67M-$8M-$10.17M-$10.43M-$16.58M
Interest expense-$438-$23-$468.68K-$475.26K-$475.9K-$470.62K-$483.53K-$470.86K
Income before taxes-$3.76M-$5.45M-$3.45M-$6.46M-$7.69M-$9.77M-$9.93M-$15.81M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.76M-$5.45M-$3.45M-$6.46M-$7.69M-$9.77M-$9.93M-$15.81M
Net income attributable to common shareholders-$3.76M-$5.45M-$3.45M-$6.46M-$7.69M-$9.77M-$9.93M-$15.81M
EBITDA-$3.98M-$5.78M-$3.48M-$6.6M-$7.94M-$10.11M-$10.37M-$16.51M
Basic earnings per share-$0.06-$0.09-$0.06-$0.11-$0.13-$0.16-$0.17-$0.27
Diluted earnings per share-$0.06-$0.09-$0.06-$0.11-$0.13-$0.16-$0.17-$0.27

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals.

Zacks Investment Research

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth.

Zacks Investment Research

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028.

Zacks Investment Research

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.

Zacks Investment Research

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.